Investigational drug · Phase 3
TQH3906
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Psoriasis, Systemic Lupus Erythematosus, Psoriatic Arthritis.
Phase 3Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
3 still active
All registered trials
6
Any phase or sponsor naming "TQH3906"
First trial start
2024
Aug 27, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TQH3906", any sponsor or status.
Conditions studied
As listed on its trial records.
- Psoriasis
- Systemic Lupus Erythematosus
- Psoriatic Arthritis
- Plaque Psoriasis
Approved drugs for the same conditions: Plaque psoriasis · Psoriatic arthritis · Lupus (SLE) · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "TQH3906" as an intervention, largest first.
- A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque PsoriasisPivotal-lookingRecruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
NCT07724366 · 400 participants (planned) · Start Sep 2, 2026 · Primary completion Sep 2027
Drug: TQH3906 capsules; Deucravacitinib tablets 6 mg and 2 more · For: Psoriasis
Sites: Beijing, China; Chongqing, China; Guangzhou, China · 45 sites in all
- Treatment of Moderate to Severe Plaque PsoriasisPivotal-lookingCompleted
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
NCT06542614 · 209 participants · Start Aug 27, 2024 · Primary completion Nov 3, 2025
Drug: TQH3906 capsules; Placebo of TQH3906 capsules · For: Plaque Psoriasis
Sites: Wuhu, China; Beijing, China; Chongqing, China · 35 sites in all
- A Clinical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus ErythematosusPivotal-lookingRecruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT07509892 · 198 participants (planned) · Start Jun 22, 2026 · Primary completion Nov 2027
Drug: TQH3906 capsule; TQH3906 placebo · For: Systemic Lupus Erythematosus
Sites: Bengbu, China; Bozhou, China; Beijing, China · 35 sites in all
- A Clinical Trial of TQH3906 Capsules in the Treatment of Active Psoriatic ArthritisPivotal-lookingRecruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
NCT07406035 · 156 participants (planned) · Start Jul 16, 2026 · Primary completion Aug 2027
Drug: TQH3906 Capsule; TQH3906 Placebo Capsule and 1 more · For: Psoriatic Arthritis
Sites: Bozhou, China; Beijing, China; Chongqing, China · 44 sites in all
- Clinical Trial of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's DiseasePivotal-lookingRecruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
NCT06754891 · 135 participants (planned) · Start Jan 28, 2025 · Primary completion Jul 2027
Drug: 24mg bid TQH3906 capsule; 32mg TQH3906 capsule and 1 more · For: Inflammatory Bowel Diseases
Sites: Bengbu, China; Wuwei, China; Guangzhou, China · 30 sites in all
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
NCT06230588 · 96 participants · Start Feb 2, 2024 · Primary completion Apr 27, 2025
Drug: TQH3906 capsule; TQH3906 placebo · For: Psoriasis
Sites: Chengdu, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Psoriasis
- HSK44459Phase 39 trials
Haisco Pharmaceutical Group Co., Ltd. · Psoriasis, Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis
- AK111Phase 32 trials
Akeso · Psoriasis, Skin Diseases, Ankylosing Spondylitis
- IBI112Phase 32 trials
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Psoriasis
- Blinded EnvudeucitinibPhase 31 trial
Alumis Inc · Plaque Psoriasis, Psoriasis (PsO), Psoriasis
- CMAB015Phase 31 trial
Taizhou Mabtech Pharmaceutical Co.,Ltd · Psoriasis
- HPP737Phase 31 trial
Newsoara Biopharma Co., Ltd. · Psoriasis
- LZM012Phase 31 trial
Livzon Pharmaceutical Group Inc. · Psoriasis
- Open-Label EnvudeucitinibPhase 31 trial
Alumis Inc · Plaque Psoriasis, Psoriasis (PsO), Psoriasis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.